3 Pipeline Obesity Treatments You Should Watch
Motley Fool
Will Obesity Drugs Gain Soon?
Motley Fool
Is Orexigen Therapeutics Burning Too Much Cash?
Motley Fool
Exciting Catalysts Approaching for This Bet
Motley Fool
Arena Faces A Convergence Of DEA And European Decisions
Seeking Alpha
Vivus Seeing Traction With Qsymia
Seeking Alpha
Vivus Gets Restrictions Loosened
Seeking Alpha
How Doctors Actually Diagnose Obesity
Motley Fool
Should Anti-Obesity Drug Company Stocks Trade In Tandem?
Seeking Alpha

